Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
ACTIVE NOT RECRUITING
NCT06579287
PHASE2

A Study of SHJ002 Sterile Ophthalmic Solution for Myopia Control

Sponsor: Sunhawk Vision Biotech, Inc.

View on ClinicalTrials.gov

Summary

The objective of this study is to explore the safety and efficacy of SHJ002 Sterile Ophthalmic Solution relative to atropine in myopia control SHJ002 is an antisense oligonucleotide to neutralize a specific microRNA.

Official title: A Phase II Study to Determine the Safety and Efficacy of SHJ002 Sterile Ophthalmic Solution on Myopia Control in Subjects Aged 3-12 Years.

Key Details

Gender

All

Age Range

3 Years - 12 Years

Study Type

INTERVENTIONAL

Enrollment

140

Start Date

2025-01-22

Completion Date

2026-12

Last Updated

2026-01-23

Healthy Volunteers

No

Interventions

DRUG

SHJ002

Topical ophthalmic

DRUG

Atropine

Topical ophthalmic

Locations (9)

Pacific Center for Advanced Vision Care Tanasbourne Vision Center

Hillsboro, Ohio, United States

Changhua Christian Hospital

Chang-hua, Taiwan

Kaohsiung Veterans General Hospital

Kaohsiung City, Taiwan

Chang Cung Memorial Hospital-Tucheng

New Taipei City, Taiwan

MacKay Memorial Hospital-Tamsui

New Taipei City, Taiwan

Chung Shan Medical University Hospital

Taichung, Taiwan

Cathay General Hospital

Taipei, Taiwan

Taipei Veterans General Hospital

Taipei, Taiwan

Tri-Service General Hospital

Taipei, Taiwan